Search - tctmd.com

Displaying 21 - 40 of 65

Sort: Relevancy | Date

Podcast TCTMD Talking Points

Lepodisiran Phase I Trial

February 07, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Top General Cardiology and Prevention News of 2022

Michael O'Riordan

December 26, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Michael O'Riordan

August 08, 2022

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

Advertisement

Lepodisiran Phase I Trial

Less Is More: Lp(a) Much More Atherogenic Than LDL

TCTMD’s Top 10 Most Popular Stories for December 2023

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Top General Cardiology and Prevention News of 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

TCTMD’s Top 10 Most Popular Stories for April 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content